SG11202102791SA - Indane derivatives for use in the treatment of bacterial infection - Google Patents

Indane derivatives for use in the treatment of bacterial infection

Info

Publication number
SG11202102791SA
SG11202102791SA SG11202102791SA SG11202102791SA SG11202102791SA SG 11202102791S A SG11202102791S A SG 11202102791SA SG 11202102791S A SG11202102791S A SG 11202102791SA SG 11202102791S A SG11202102791S A SG 11202102791SA SG 11202102791S A SG11202102791S A SG 11202102791SA
Authority
SG
Singapore
Prior art keywords
treatment
bacterial infection
indane derivatives
indane
derivatives
Prior art date
Application number
SG11202102791SA
Other languages
English (en)
Inventor
Simon Leiris
David Thomas Davies
Martin Everett
Nicolas Sprynski
Lilha Beyria
Thomas David Pallin
Andrew Peter Cridland
Toby Jonathan Blench
Richard Leonard Elliott
David Edward Clark
Original Assignee
Antabio Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18290106.6A external-priority patent/EP3628666A1/en
Application filed by Antabio Sas filed Critical Antabio Sas
Publication of SG11202102791SA publication Critical patent/SG11202102791SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202102791SA 2018-09-25 2019-07-25 Indane derivatives for use in the treatment of bacterial infection SG11202102791SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18290106.6A EP3628666A1 (en) 2018-09-25 2018-09-25 Indane derivatives for use in the treatment of bacterial infection
EP18290104 2018-09-26
EP18197365 2018-09-27
PCT/EP2019/070115 WO2020064173A1 (en) 2018-09-25 2019-07-25 Indane derivatives for use in the treatment of bacterial infection

Publications (1)

Publication Number Publication Date
SG11202102791SA true SG11202102791SA (en) 2021-04-29

Family

ID=67439236

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202102791SA SG11202102791SA (en) 2018-09-25 2019-07-25 Indane derivatives for use in the treatment of bacterial infection
SG11202102790PA SG11202102790PA (en) 2018-09-25 2019-07-25 Indane derivatives for use in the treatment of bacterial infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202102790PA SG11202102790PA (en) 2018-09-25 2019-07-25 Indane derivatives for use in the treatment of bacterial infection

Country Status (14)

Country Link
US (2) US20220112169A1 (es)
EP (2) EP3856730A1 (es)
JP (2) JP7429993B2 (es)
KR (2) KR20210087448A (es)
CN (2) CN113166085B (es)
AU (2) AU2019351551A1 (es)
BR (2) BR112021005532A2 (es)
CA (2) CA3113697A1 (es)
CL (2) CL2021000729A1 (es)
IL (2) IL281780A (es)
MA (2) MA53706A (es)
MX (2) MX2021003485A (es)
SG (2) SG11202102791SA (es)
WO (2) WO2020064174A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166085B (zh) * 2018-09-25 2024-04-09 安塔比奥公司 用于治疗细菌感染的茚满衍生物
US20240016941A1 (en) * 2020-03-24 2024-01-18 Antabio Sas Combination therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
JP3126541B2 (ja) * 1993-03-26 2001-01-22 千寿製薬株式会社 ベンゾチアゾール誘導体、その製法及びその用途
JPH0782259A (ja) * 1993-09-14 1995-03-28 Senju Pharmaceut Co Ltd スクシンアミド酸誘導体及びそれを含有する糖尿病合併症治療剤
JPH11130761A (ja) * 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
AU2005282466B2 (en) 2004-09-08 2011-03-10 Merck Sharp & Dohme Corp. Monocyclic anilide spirolactam CGRP receptor antagonists
FR2883876B1 (fr) 2005-03-30 2007-05-04 Servier Lab Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2006125511A1 (de) 2005-05-25 2006-11-30 Merck Patent Gmbh Pyran-dioxan-derivate und deren verwendung in flüssigkristallinen medien
KR101583487B1 (ko) 2007-06-05 2016-01-08 사노피 치환된 벤조일아미노-인단-2-카복실산 및 관련된 화합물
EP2141164A1 (en) * 2008-07-01 2010-01-06 Mutabilis New 1,2,4-triazine derivatives and biological applications thereof
US8877815B2 (en) * 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
MX2015006328A (es) * 2012-11-30 2015-09-07 Bayer Cropscience Ag Mezcla fungicida o pesticida binaria.
GB201704476D0 (en) * 2017-03-21 2017-05-03 Antabio Sas Chemical compounds
CN113166085B (zh) 2018-09-25 2024-04-09 安塔比奥公司 用于治疗细菌感染的茚满衍生物

Also Published As

Publication number Publication date
SG11202102790PA (en) 2021-04-29
JP7429993B2 (ja) 2024-02-09
CN113166085A (zh) 2021-07-23
EP3856730A1 (en) 2021-08-04
JP2022502485A (ja) 2022-01-11
KR20210087025A (ko) 2021-07-09
KR20210087448A (ko) 2021-07-12
JP2022502486A (ja) 2022-01-11
WO2020064173A1 (en) 2020-04-02
CL2021000729A1 (es) 2021-11-05
CN113166085B (zh) 2024-04-09
MA53707A (fr) 2021-12-29
US20210347748A1 (en) 2021-11-11
CN113166084A (zh) 2021-07-23
CL2021000731A1 (es) 2021-11-05
IL281770A (en) 2021-05-31
BR112021005651A2 (pt) 2021-06-22
IL281780A (en) 2021-05-31
MX2021003485A (es) 2021-09-10
EP3856729A1 (en) 2021-08-04
US20220112169A1 (en) 2022-04-14
MX2021003498A (es) 2021-09-10
CA3113689A1 (en) 2020-04-02
MA53706A (fr) 2021-12-29
BR112021005532A2 (pt) 2021-06-29
AU2019349438A1 (en) 2021-04-15
WO2020064174A1 (en) 2020-04-02
CA3113697A1 (en) 2020-04-02
CN113166084B (zh) 2024-06-04
AU2019351551A1 (en) 2021-04-15
JP7429992B2 (ja) 2024-02-09

Similar Documents

Publication Publication Date Title
EP3838239A4 (en) MEDICAL ASSOCIATION
EP3390357A4 (en) BIARYLMONOBACTAM COMPOUNDS AND CORRESPONDING METHODS OF USE FOR THE TREATMENT OF BACTERIAL INFECTIONS
IL271863B (en) Compounds and their use for the treatment of microbial infections
EP3576738A4 (en) USE OF GABOXADOL TO TREAT TINNITUS
ZA202103977B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
IL264232A (en) Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
IL278895A (en) Diltiazem for use in the treatment of microbial infections
IL281775A (en) Methods of treating infections using bacteria
IL281770A (en) History of indan for the treatment of bacterial infection
HK1243951A1 (zh) 抗微生物組合和其在治療微生物感染中的用途
ZA202002069B (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
PL3497095T3 (pl) Związki chelatujące cynk do stosowania w leczeniu zakażenia bakteryjnego
EP3285787B8 (en) Treatment of bacterial infections in aquaculture
DK3630111T3 (en) Compounds and methods for treating bacterial infections
EP3856747C0 (en) SUBSTITUTE PYRIDOINDOLES FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION
EP3761979A4 (en) USE OF GABOXADOL TO TREAT SUBSTANCE ABUSE
EP3609578A4 (en) PHARMACEUTICAL COMBINATION AND ITS USE FOR THE TREATMENT OF SYNUCLEINOPATHIES
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL253418A0 (en) Nisin-based compounds and their use in the treatment of bacterial infections
EP3694391A4 (en) DEVICE INTENDED FOR USE IN THE TREATMENT OF HEMORROIDS
PL3618806T3 (pl) Kompozycja do leczenia aft i owrzodzeń jamy ustnej
EP3538094A4 (en) FORMULATIONS, METHODS, KIT AND PHARMACEUTICAL FORMS FOR TREATING BACTERIAL INFECTIONS
IL281969A (en) New medical use of oxalate-reducing bacteria
EP3579843A4 (en) 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN MEDICAL TREATMENT